Transformil-18 enhances cancer immunotherapy.

Cytokine is a secreted protein that can be used in immunotherapy for tumorsbut because the specificity of its treatment is not ideal, and may be toxic, so clinical application is limitedIL-18 is a member of the IL-1 cytokine family that activates congenital lymphocytes and T cellsits role in anti-tumor has been widely studied in recent years because il-18 can induce the proliferation and increase its activity in immune cellscytokine IL-18 was highly anticipated in cancer immunotherapy due to excellent immune enhancement, but several related clinical studies have not achieved satisfactory resultsrecently published in nature in a paper giving the latest explanationarticle entitled "IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy"research team from Yale University found that IL-18 failed to perform anti-tumor effects in the body because cancer cells secreted large amounts of IL-18 competitive binding antibody IL-18 BP, resulting in IL-18 unable to bind to the lymphocyte-specific receptor IL-18R alpha, greatly reducing its ability to enhance immunitybased on this, the researchers screened a subtype DR-18 that would not bind to IL-18 BP from 250 million variants of IL-18, combined with PD-1 inhibitors, and achieved unexpected results in the mouse model of melanoma and colorectal cancer, with tumor shrinkage significantly and a significantly longer survival in mice with a lotus tumorFurther analysis of theshowed that THE excellent anti-tumor effect of DR-18 came from the activation of a variety of immune cells inside the tumor, including CD8-T cells, NK cells and intra-tumor stem cell-like T cells, altering the immune microenvironmentpeer experts to this study highly appraised, think that the results are very promising, especially for "cold tumors" have important therapeutic value()